Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Nov 15;184(10):1107-13.
doi: 10.1164/rccm.201106-0995PP. Epub 2011 Aug 25.

Tuberculosis drug development: ensuring people living with HIV are not left behind

Anne F Luetkemeyer  1 , Haileyesus Getahun, Gabriel Chamie, Christian Lienhardt, Diane V Havlir
Affiliations

Tuberculosis drug development: ensuring people living with HIV are not left behind

Anne F Luetkemeyer et al. Am J Respir Crit Care Med. .

Abstract

An unprecedented number of new tuberculosis (TB) medications are currently in development, and there will be great pressure to deploy these new drugs among all populations after their efficacy is demonstrated. People living with HIV experience a large burden of TB and have a particularly pressing need for TB treatments that are shorter and less toxic. In addition, all people living with HIV now require antiretroviral therapy during TB treatment. A roadmap of the research, programmatic, and regulatory considerations includes the following: (1) inclusion of people living with HIV early in clinical trials for treatment and prevention using new TB medications, (2) prioritization of key studies of HIV-TB drug interactions and interactions between new TB agents, and (3) optimization of clinical trial infrastructure, laboratory capacity, and drug susceptibility testing.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Timeline for inclusion of people living with HIV in TB drug development. ART = antiretroviral therapy; EBA = early bactericidal activity study; SSCC = serial sputum colony counting study; TB = tuberculosis. Adapted from Ginsberg and colleagues (33).
See this image and copyright information in PMC

References

    1. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med 2010;16:186–193 - PubMed
    1. Ma Z, Lienhardt C, McIlleron H, Nunn AJ, Wang X. Global tuberculosis drug development pipeline: the need and the reality. Lancet 2010;375:2100–2109 - PubMed
    1. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A, Gengiah T, Nair G, Bamber S, Singh A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010;362:697–706 - PMC - PubMed
    1. Havlir D, Ive P, Kendall M, Luetkemeyer A, Swindells S, Kumwenda J, Qasba S, Hogg E, Anderson J, Sanne I. International randomized trail of immediate vs. early ART in HIV+ patients treated for TB: ACTG 5221 STRIDE study. Presented at the 18th Conference on Retroviruses and Opportunistic Infections. February 27–March 2, 2011, Boston, MA: Abstract 38
    1. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y, Marcy O, Chan S, Prak N, et al. Significant enhancement in survival with early (2 weeks) vs. late (8 weeks) initiation of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis (Abstract THLBB106). Presented at the International AIDS Conference. August 18–23, 2010, Vienna, Austria

Publication types

MeSH terms